MedTrace Logo

ANGIOPREDICT. ICORG 12-16, V3

NCT01822444 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 76

Last updated 2026-04-13

No results posted yet for this study

Summary

Primary Objective:

The primary objective is to validate previously identified predictive/prognostic genomic DNA and expression biomarkers of response to combination bvz treatments in K-ras mutant advanced CRC (a CRC) or metastatic CRC (mCRC).

Secondary Objective:

1. To test the efficacy of bvz in combination with FOLFOX in patients with newly diagnosed advanced or metastatic K-ras mutant CRC and
2. To determine the progression free and overall survival of patients under first line FOLFOX + bvz in aCRC or mCRC.

Conditions

  • Advanced Colorectal Cancer

Interventions

OTHER

Biomarker analysis

Sponsors & Collaborators

  • Cancer Trials Ireland

    lead NETWORK

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • Germany
  • Ireland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01822444 on ClinicalTrials.gov